SCHEMBL457622

SCHEMBL457622

CC(C)(C)OC(=O)NNC(=S)Nc1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.64
ALDH1A1 P00352 4/20 0.64
LMNA P02545 3/20 0.56
ALOX12 P18054 1/20 0.56
PKM P14618 1/20 0.56
NOX1 Q9Y5S8 2/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
POLB P06746 1/20 0.54
PLK4 O00444 1/20 0.52
DAPK3 O43293 1/20 0.52
RPS6KA5 O75582 1/20 0.52
MAP4K4 O95819 1/20 0.52
ERBB2 P04626 1/20 0.52
PRKCG P05129 1/20 0.52
PIM1 P11309 1/20 0.52
PHKG2 P15735 1/20 0.52
CDK2 P24941 1/20 0.52
AXL P30530 1/20 0.52
AKT1 P31749 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28679366 0.84 GAA (0.71) GAAALDH1A1LMNAALOX12PKM
SCHEMBL12237514 0.84 GAA (0.62) GAAALDH1A1LMNAPKMMEN1
SCHEMBL632848 0.82 MEN1 (0.54) ALDH1A1LMNAALOX12MEN1KMT2A
SCHEMBL31090335 0.81 GAA (0.61) GAAALDH1A1LMNAPKMMAP4K4
SCHEMBL5100819 0.80 ALDH1A1 (0.51) GAAALDH1A1LMNAALOX12MEN1
SCHEMBL31606832 0.80 GAA (0.50) GAAALDH1A1LMNAALOX12MEN1
SCHEMBL2108776 0.79 GAA (0.44) GAAALDH1A1LMNAALOX12MEN1
SCHEMBL5097622 0.79 ALDH1A1 (0.50) GAAALDH1A1LMNAALOX12MEN1
SCHEMBL469849 0.79 NOX1 (0.84) GAAALDH1A1LMNAALOX12PKM
SCHEMBL19277757 0.78 KMT2A (0.74) GAAALDH1A1LMNAALOX12NOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2240175-B1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY US GOV HEALTH & HUMAN SERV (US) 2013-01-02 EP disclosed
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY ABCC1, ABCB1, ABCC2 GAA 231/4885ALDH1A1 1607/4885LMNA 3303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.